Speaker Profile
Robert Wild

Robert Wild PhD

Clinical Pharmacology
South San Francisco, California, United States of America

Connect with the speaker?

Dr. Wild joined Dracen Pharmaceuticals in 2017 as Chief Scientific Officer (CSO) and was instrumental in the successful fund raising leading to Dracen’s Series A financing. He is responsible for all discovery, preclinical development and translational research efforts of Dracen’s therapeutic pipeline and leads scientific strategy within the company. Dr. Wild is also an Executive-in-Residence with ShangPharma Innovation, an innovative healthcare VC firm. Dr. Wild is a seasoned R&D executive with close to two decades of broad biotech/pharma industry experience in drug discovery and development, spanning both small molecules and biologics. Throughout his career, Dr. Wild has contributed to the advancement of numerous clinical development candidates, including four FDA-approved oncology therapeutics (sunitinib, cetuximab, dasatinib and erlotinib). Before Dracen Pharmaceuticals, Dr. Wild served as CSO and Senior Vice President of Research at Ignyta, Inc. (acquired by Roche); CSO Oncology Research at Eli Lilly & Company; Senior Director at OSI Pharmaceuticals (a wholly owned subsidiary of Astellas Pharma); and as a Senior Research Investigator at Bristol-Myers Squibb and SUGEN, Inc. (acquired by Pharmacia/Pfizer). Dr. Wild is a native of Germany and received his undergraduate and graduate degrees at the University of Minnesota, Minneapolis.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)